Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | +3.34% | +6.58% | -61.51% |
Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
Apr. 02 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.51% | 81.34M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.22% | 29.48B | |
+57.35% | 25.43B | |
-18.14% | 11.49B | |
-44.02% | 11.3B | |
-15.61% | 11.1B | |
+4.34% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- Piper Sandler Starts Gritstone bio at Overweight With $6 Price Target